Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

57.48
-0.6300-1.08%
Post-market: 57.900.4200+0.73%19:57 EDT
Volume:65.85M
Turnover:3.78B
Market Cap:117.02B
PE:16.61
High:58.55
Open:58.26
Low:56.91
Close:58.11
52wk High:62.89
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:5.73
T/O Rate:3.24%
Dividend:2.49
Dividend Rate:4.33%
EPS(TTM):3.46
EPS(LYR):3.46
ROE:40.44%
ROA:10.29%
PB:6.33
PE(LYR):16.61

Loading ...

A Look At Bristol Myers Squibb (BMY) Valuation After Recent Reblozyl And Iberdomide Milestones

Simply Wall St.
·
Feb 25

Bristol-Myers Squibb Initiated at Sector Perform by RBC Capital

Dow Jones
·
Feb 25

NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

prnewswire
·
Feb 25

Berenberg Lifts Price Target on Bristol-Myers Squibb to $60 From $57, Keeps Hold Rating

MT Newswires Live
·
Feb 25

ROVI FY 2025 Okedi sales hit EUR 56.7 million, up 97%

Reuters
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

Bristol-Myers Squibb Co : Berenberg Raises Target Price to $60 From $57

THOMSON REUTERS
·
Feb 25

Bristol Myers initiated with a Sector Perform at RBC Capital

TIPRANKS
·
Feb 25

How Investors May Respond To Bristol Myers Squibb (BMY) Iberdomide Priority Review And Reblozyl Trial Progress

Simply Wall St.
·
Feb 24

Bristol Myers Squibb to Join TD Cowen 46th Annual Health Care Conference Fireside Chat

Reuters
·
Feb 24

US Supreme Court won't bite in Cracker Barrel case over scope of wage law

Reuters
·
Feb 24

Bristol-Myers Squibb’s New Rheumatoid Arthritis Trial: What Early Pipeline Moves Mean for BMY Investors

TIPRANKS
·
Feb 24

Piper Sandler Adjusts Price Target on Bristol-Myers Squibb to $75 From $66, Maintains Overweight Rating

MT Newswires Live
·
Feb 23

BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept

Reuters
·
Feb 23

Bristol Myers Squibb reports positive Phase 2 registrational results for Reblozyl in adult alpha thalassemia

Reuters
·
Feb 23

Bristol-Myers Squibb Co - Cohorts Met Primary and Secondary Endpoints

THOMSON REUTERS
·
Feb 23

Bristol-Myers Squibb Co - Safety Findings Consistent With Known Profile of Reblozyl in Thalassemia

THOMSON REUTERS
·
Feb 23

Bristol-Myers Squibb Co - Reblozyl Showed Significant Decrease in RBC Transfusion Burden

THOMSON REUTERS
·
Feb 23

Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study of Luspatercept in Adults With Alpha (Α)-Thalassemia

THOMSON REUTERS
·
Feb 23

U.S. RESEARCH ROUNDUP-Akamai Technologies, Albemarle, Nordson

Reuters
·
Feb 23